Antibleeding Gel Market - Forecast(2021 - 2026)

Report Code: HCR 0587 Report Format: PDF + Excel (Delivery in 48 Hrs)

Antibleeding Gel Market Overview

Antibleeding Gel Market size is estimated to be $4.7 billion in 2019, growing at a CAGR of 6.1% during the forecast period 2020-2025. Antibleeding gel is a semi-clear gel that instantly stops the internal and external bleeding. The gel stops bleeding and speeds along the process of healing and also works to stick blood platelets together to active clotting factor, which leads to beginning of healing process. Rising number of road accidents coupled with the increase in the number of people suffering from psychological trauma is a significant factor contributing to its market growth. Besides this, the introduction of vetigel for veterinary is also fueling the market growth. Vetigel is a 5ml syringe of gel comprised of two Biopolymers, when directly applied to the source of bleeding it rapidly adheres to the wound-site and stops the flow of bleeding by creating a mechanical barrier. Moreover, according to the NCBI trauma is the leading cause of death and disability in the United States. For children and adults younger than age 45, trauma accounts for an estimated 79,000 deaths each year compared to 49,000 non-communicable disease deaths and 15,000 infectious disease deaths.

Report Coverage

The report: “Antibleeding Gel Market Forecast (2020-2025)”, by IndustryARC, covers an in-depth analysis of the following segments of the Antibleeding Gel Market.
By Product Type-  Veterinary Use and Human Use.
By Indication - Biopsies of Soft Tissue, Trauma, Enucleations, Orthopedic Surgeries and Others.
By Distribution Channel - Retail Pharmacy, Online Pharmacy, Veterinary Pharmacy and Others.
By Geography - North America, Europe, Asia Pacific and Rest of the World.

Key Takeaways

  • Veterinary Use held the major market share in 2019 owing to the rising number of animal’s road injuries.
  • Retail Pharmacy accounted for the largest market share in 2019 owing to the ease of availability of antibleeding gel.
  • North America dominated the Antibleeding Gel Market owing to the rising number of trauma injuries cases in the United States.
  • Rising Number of Road Accidents is a major factor driving Antibleeding Gel Market during the forecast period 2020-2025.

Antibleeding Gel Market Segment Analysis - By Product Type 

By Product Type, the Antibleeding Gel Market is segmented into Veterinary Use and Human Use. Veterinary Use held the major market share in 2019 owing to the rising number of animal’s road injuries. Vetigel is a simple gel made from natural algae-based polymer which cooperate with the native cellular clotting signals to accelerate hemostasis. Moreover, it is a fast acting, bioresorbabale gel used to stop bleeding in seconds. The product is designed for veterinarians bleeding internally and externally which is made to stop minor or severe wounds in animal without manual pressure. In addition, when it is applied to a wound it speeds up the body production of fibrin which helps in blood clotting. Furthermore, according to Insurance Institute of Highway Safety from 1975 to the mid-2000s there was a general upward trend in death from collision with animals with 211 deaths in 2017. Also, human use segment is projected to witness growth at fastest CAGR of 6.8% in forecast period 2020-2025. Moreover, Prevest Hemostat Gel is a 25% buffered aluminum chloride thixotropic, non-dripping gel for stopping minor gingival bleeding in restorative procedures, placement of metal bands, cervical matrices and crown preparation.

Antibleeding Gel Market Segment Analysis - By Distribution Channel

Retail Pharmacy accounted for the largest market share in 2019 owing to the ease of availability of antibleeding gel. The retail pharmacy is an independent avenue that provides branded or generic medicines to the public with or without prescription. In addition, government and medical bodies have levied multiple regulations to ensure proper and secure functioning of retail pharmacy which is a major factor contributing to segment revenue. Furthermore, the growth of this segment is majorly due to the increasing number of people injured in road accidents.

Antibleeding Gel Market Segment Analysis - Geography

North America dominated the Antibleeding Gel Market with a region share of more than 30% in 2019 followed by Europe and APAC. Growing population along with the increase in the number of people suffering from trauma injuries in the United States, increasing funding by government bodies, rising healthcare expenditure and increasing health concern among people is a major factor propelling the market growth. Furthermore, the presence of major players including Cresilon is further contributing to the market growth.

Antibleeding Gel Market Drivers

Large Number of People Suffering from Trauma Injuries

Large number of people suffering from trauma injuries is a major driving the Antibleeding Gel Market during the forecast period 2020-2025. Moreover, trauma injuries are a result of wide variety of blunt, penetrating and burn mechanism. They include motor vehicle collision, sports injuries, falls, natural disaster and a multitude of other physical injuries which occur in the home, on the street, while at work which requires immediate care. Furthermore, according to the American Association for the Surgery of Trauma in the U.S. injury accounts for over 150,000 deaths and over 3 million non-fatal injuries per year.

Rising Number of Road Accidents

Rising Number of Road Accidents is a major factor driving Antibleeding Gel Market during the forecast period 2020-2025. Moreover, according to World Health Organization every year approximately 1.35 million are cut short as a result of road traffic crash. Between 20 and 50 million more people suffer from non-fatal injuries, with many incurring disabilities as a result of injury. In addition, road traffic injuries cause considerable economic losses to individuals, families and to notation as a whole. 

Antibleeding Gel Market Challenges

Side-Effects of Antibleeding Gel

Side-effects of antibleeding gel serves as a major setback for the growth of the Antibleeding Gel Market during the forecast period 2020-2025. Moreover, thrombi gel sometimes can lead to bloody stools, bleeding gums, blood in the urine, coughing up blood, headache which hampers its market growth in the future.

Antibleeding Gel Market Industry Outlook 

Product Launches, Merger & Acquisition, joint ventures and R&D activities are key strategies adopted by the players in Antibleeding Gel Market. Antibleeding Gel Market top 10 companies are Cresilon Inc., Baxter Healthcare Corporation, Z-Medica, Steve Kelly, Ethicon, Pfizer Inc., CR Bard, Hemcon Medical Technologies Inc., Abbott Laboratories and Johnson & Johnson.

Note: Antibleeding Gel Market has no developments in the previous 5 years.

1. Antibleeding Gel Market Overview
    1.1 Definitions and Scope
2. Antibleeding Gel Market - Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Product Type
    2.3 Key trends by Indication
    2.4 Key trends by Distribution Channel
    2.5 Key trends by Geography
3. Antibleeding Gel Market –Comparative Analysis
    3.1 Product Benchmarking - Key companies
    3.2 Financials Analysis - Key Companies
    3.3 Market Share Analysis- Key Companies
    3.4 Patent Analysis 
    3.5 Pricing Analysis
4. Antibleeding Gel Market- Startup companies Scenario Premium Premium 
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Antibleeding Gel Market – Industry Market Entry Scenario Premium Premium 
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Antibleeding Gel Market Forces
    6.1 Market Drivers
    6.2 Market Constraints
    6.3 Porters Five Force Model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes 
7. Antibleeding Gel Market -Strategic analysis
    7.1 Value chain analysis 
    7.2 Opportunities analysis
    7.3 Market life cycle
8. Antibleeding Gel Market – By Product Type (Market Size – $Million/$Billion)
    8.1 Veterinary Use
    8.2 Human Use
9. Antibleeding Gel Market – By Indication (Market Size – $Million/$Billion)
    9.1 Biopsies of Soft Tissue
    9.2 Trauma
    9.3 Enucleations
    9.4 Orthopedic Surgeries
    9.5 Others
10. Antibleeding Gel Market – By Distribution Channel (Market Size – $Million/$Billion)
    10.1 Retail Pharmacy
    10.2 Veterinary Pharmacy
    10.3 Online Pharmacy
    10.4 Others
11. Antibleeding Gel Market - By Geography (Market Size - $Million/$Billion)
    11.1 North America
        11.1.1 U.S.
        11.1.2 Canada
        11.1.3 Mexico
    11.2 Europe
        11.2.1 U.K.
        11.2.2 Germany
        11.2.3 France
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Rest of Europe
    11.3 Asia-Pacific
        11.3.1 China
        11.3.2 Japan
        11.3.3 South Korea
        11.3.4 India
        11.3.5 Australia & New Zealand
        11.3.6 Rest of APAC
    11.4 Rest of the World
        11.4.1 Middle East
        11.4.2 Africa
        11.4.3 South America
12. Antibleeding Gel Market - Entropy
13. Antibleeding Gel Market – Industry/Segment Competition Landscape Premium 
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key companies
        13.1.3 Market Share by Country- Key companies
        13.1.4 Best Practices for Companies
14. Antibleeding Gel Market – Key Company List by Country Premium Premium
15. Antibleeding Gel Market Company Analysis
    15.1 Company Revenue, Products, M&A, Developments
    15.2 Cresilon Inc.,
    15.3 Baxter Healthcare Corporation
    15.4 Z-Medica
    15.5 Steve Kelly
    15.6 Ethicon
    15.7 Pfizer Inc.,
    15.8 CR Bard
    15.9 Hemcon Medical Technologies Inc.,
    15.10 Abbott Laboratories
    15.11 Johnson & Johnson`
*Financials for private companies would be provided on a best efforts basis”.